Clinical Trial Details
— Status: Recruiting
Administrative data
NCT number |
NCT04553536 |
Other study ID # |
ZGuo20200826 |
Secondary ID |
|
Status |
Recruiting |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
November 2, 2020 |
Est. completion date |
January 31, 2024 |
Study information
Verified date |
January 2024 |
Source |
Second Hospital of Shanxi Medical University |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Pain is 'a double-edged sword', disturbing daily life of the sufferers and activating the
intrinsic protective mechanisms. Transient receptor potential vanilloid 1 (TRPV1), play such
role as 'a double agent', transmitting the pain signals and initiating the cardio-protective
mechanism via release protective neuropeptides.
Surgery-related pain is mostly so severe and disturbing that must be medically treated.
Unfortunately, the beneficial aspect of pain is commonly ignored in daily clinical practice.
Does it matter to the patients' outcomes? We don't know yet! What we have been seeing is the
shocking outcomes of patients underwent surgery, which shows about 0.8% and 7% of mortalities
in the period of 48 hours and 30 days after surgery, respectively
(https://www.rcplondon.ac.uk/projects/outputs/national-hip-fracture-database-annual-report-20
16; Injury. 2017; 48(10): 2180-2183). What causes the disaster? Piles of evidence demonstrate
that deep anesthesia or deep sedation is related to the high mortality of the patients
(Anesthesiology. 2012; 116:1195-1203; Crit Care. 2014; 18(4):R156 ). What about the effect of
analgesia, especially the over-analgesia, on the patients' outcome in and after surgery?
Opioids are the most commonly used drugs in the treatment of moderate and sever pain
including intra- and postoperative pain. The µ-opioid receptor agonists induce analgesic
effect via inhibition of the transduction and the transmission of pain signals, by
suppression of the release of CGRP and SP from the nerve terminals. The protective effects on
cardiovascular system mediated by CGRP and SP can be inhibited, if the same effect is
produced by the action of opioids in the peripheral nerve terminals innervating the heart and
the vasculature. Our previous research shows that intrathecal administration of morphine or
epidural administration of ropivacaine (1%, in 20 μL) significantly attenuates the increases
of CGRP and its coding mRNA in ventricular myocardium and the innervating dorsal root
ganglion neurons following occlusion of coronary artery in experimental animals. We design
this study to investigate the potential adverse effect of anesthesia with opioid as the main
analgesic.
Description:
We hypothesize that over-analgesia using opioids significantly suppresses the activity of
TRPV1/CGRP and SP and reduces the amount of CGRP and SP released, which results in an
effective de-protection of the cardiovascular system. The severer myocardial damage under
some insulting circumstances and eventful systemic hemodynamics is likely occurring upon some
surgical/pathological/pharmacological insults in the intra- and postoperative periods.
This parallel, randomized controlled trial will be conducted in eleven centers in Shanxi
province, China, which is designed to investigate the perioperative incidence of adverse
cardiovascular events and alteration of cardiac troponin I (cTnI) in the patients (one
thousand patients, ASA Physical Status 1-II, older than 16 years, regardless of the gender)
undergoing surgery under total intravenous general anesthesia with conventional µ-opioid
agonists or Esketamine, as the major analgesic. Clinically appropriate anesthesia depth or
BIS readings will be used for judgement of anesthetic depth. Conventional monitoring
parameters, including blood pressures, heart rate, SpO2 and ECG, will be recorded and
analyzed. Blood samples will be collected at 30 min before induction of anesthesia, at the
end of surgery and 24 h after the surgery. The association of the perioperative adverse
cardiovascular events and the alterations of the levels of serum TRPV1, CGRP, SP and cTnI in
the patients underwent general anesthesia using different analgesics (µ-opioid agonists vs
Esketamine) will be evaluated. Postoperative outcome, including the functions of the brain
and cardiovascular system, is also going to be traced for 1 year postoperatively.